Terns Pharmaceuticals, Inc.

NASDAQ:TERN

4.66 (USD) • At close February 5, 2025
Bedrijfsnaam Terns Pharmaceuticals, Inc.
Symbool TERN
Munteenheid USD
Prijs 4.66
Beurswaarde 395,815,274
Dividendpercentage 0%
52-weken bereik 4.165 - 11.4
Industrie Biotechnology
Sector Healthcare
CEO Dr. Erin Quirk M.D.
Website https://www.ternspharma.com

An error occurred while fetching data.

Over Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201,

Vergelijkbare Aandelen

Biomerica, Inc. logo

Biomerica, Inc.

BMRA

0.506 USD

Oncternal Therapeutics, Inc. logo

Oncternal Therapeutics, Inc.

ONCT

0.527 USD

Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc.

CRBP

11.33 USD

Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc.

TPST

0.936 USD

AVROBIO, Inc. logo

AVROBIO, Inc.

AVRO

1.4 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)